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INTRODUCTION
Many studies have attempted to identify predictors of a poor 
prognosis for breast cancer. Breast cancer can be classified into 
five major subtypes based on gene expression signature; lumi-
nal A, luminal B, normal breast-like, human epidermal growth 
factor receptor (HER2), and basal-like. Among these, basal-
like breast cancer (BLBC) is associated with a poor prognosis, 
because these cancers are highly proliferative and invasive, and 
they metastasize rapidly to the lung and brain [1]. The molecular 
classification of breast cancer has provided new prognostic fac-
tors. One of the molecules related to prognosis is αB-crystallin, 
which was thought to be associated with a poor prognosis in 
many studies. αB-crystallin is a member of the conserved small 
heat shock protein and is expressed in diverse malignancies. 
Crystallins, including αB-crystallin, are soluble proteins found 
primarily in the lens of the eye, and αB-crystallin is found in 
normal and diseased non-lenticular tissue [2]. Indeed, αB-
crystallin has been found in malignant diseases such as glio-
mas, renal cell carcinomas, and breast carcinomas [3-5], and 
its expression correlates with poor clinical outcomes in breast 
and head and neck carcinomas [5-7]. Recent studies have indi-
cated that αB-crystallin is expressed in BLBCs and likely con-
tributes to their aggressive phenotype [8]. But, it is unknown 
whether αB-crystallin overexpression is driven by promoter 
transactivation, loss of transcriptional inhibition, increased 
DNA copy number, or by other means, such as a mutation of 
promoter elements [7]. αB-crystallin influences cytoprotective 
effects by functioning as a molecular chaperone to inhibit in-
tracellular protein aggregation. Additionally, αB-crystallin in-
hibits apoptosis in response to many different stimuli, includ-
ing chemotherapy drugs, tumor necrosis factor-α, tumor ne-
crosis factor-related apoptosis-inducing ligand, and reactive 
oxygen species through the cell death protease caspase-3 and 
by preventing the mitochondrial translocation of proapoptotic 
Bcl-2 family members such as Box [2-6]. 
A recent study indicated that αB-crystallin is expressed in 
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BLBCs and predicts poor survival independent of tumor grade, 
lymph node metastases, estrogen receptor (ER) or HER2 sta-
tus [7]. Furthermore, αB-crystallin is expressed more in breast 
cancers with lymph node metastasis [5]. Although the anti-
apoptotic function of αB-crystallin is thought to be related to 
such a poor breast cancer prognosis, clinical studies are insuf-
ficient. 
The objective of this study was to investigate the correlation 
between αB-crystallin expression and established prognostic 
factors such as molecular subtypes, histological grade, and 
lymph node metastasis. Furthermore we wanted to determine 
whether αB-crystallin is a novel predictor of aggressive breast 
cancer.
METHODS
Patients and tissue specimens
Eighty-two invasive ductal carcinomas (IDC) were obtained 
from surgical resections conducted at the Department of Sur-
gery at Hallym Sacred Heart Hospital from August 2002 to 
June 2006. Ipsilateral axillary lymph node dissection was per-
formed in all cases. All samples were paraffin-embedded, and 
whole tissue sections were previously fixed in 10% neutral buff-
ered formalin or an alcoholic formalin mixture. Clinicopatho-
logical factors were evaluated, including age at initial diagno-
sis, tumor size, lymph node metastasis, lymphovascular inva-
sion, histological grade, and tumor markers such as ER, pro-
gesterone receptor (PR), and HER2. The histological grade 
was assessed by a modified Bloom-Richardson-Scarff grading 
system. Tumor marker positivity was evaluated based on pa-
thology reports. We considered HER2 staining scores of 2 and 
3 as HER2 positive.
Tissue microarray block
Hematoxylin and eosin tissue sections were reviewed by a 
pathologist, who selected areas of invasive tumor to be placed 
on a tissue microarrary, for each case included in the study. 
Five μm thick sections were cut and placed on a tissue micro-
array. 
Immunohistochemistry
Slides were incubated for 30 minutes, deparaffinized, and 
rinsed. Heat antigen unmasking was performed for 20 min-
utes, followed by the addition of primary antibody (1:200, 
anti-αB-crystallin) for 1 hour at room temperature. After wash-
ing, the secondary antibody was added for 30 minutes at room 
temperature. αB-crystallin immunohistochemistry was per-
formed using a commercially available monoclonal antibody 
Figure 1. αB-crystallin expression scoring. Staining was graded as follows: 0, negative staining; 1, weakly positive staining; 2, moderately positive 
staining; 3, highly positive staining (Immunohistochemical staining for αB-crystallin, ×100).
(A) Score=0, (B) Score=1, (C) Score=2, (D) Score=3.
A
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B
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to αB-crystallin (1:200 in antibody diluents, SPA-222; Stress-
gen Biotechnologies, Victoria, Canada). 
Scoring of αB-crystallin staining 
Cytoplasmic expression of αB-crystallin was scored using a 
four-tiered system. Staining was graded as follows: 0, negative 
staining; 1, weakly positive staining; 2, moderately positive 
staining; 3, highly positive staining in cytoplasm (Figure 1). 
αB-crystallin expression was analyzed according to various 
clinical and biological characteristics such as tumor size, lymph 
node metastasis, lymphovascular invasion, histological grade, 
tumor markers such as ER, PR, HER2, and time to recurrence.
Statistical analysis
DBSTAT software version 4.1 (DBSTAT Co., Seoul, Korea) 
was used. Correlations between αB-crystallin and clinico-
pathological characteristics were assessed using chi-square 
and Fisher’s exact tests. Time to recurrence between the αB-
crystallin positive and negative groups was analyzed by the 
Kaplan-Meier method. A p<0.05 was considered significant.
RESULTS
Patient age ranged from 28-76 years with a median age of 53 
years. The mean follow-up period was 50 months. All of the path-
ological types were IDC. Nine cases of distant metastasis to 
bone, lung, liver, adrenal gland and the leptomenix were found. 
Immunohistochemical staining for αB-crystallin 
Twenty nine tumors (35.4%) had no cytoplasmic αB-crystallin 
staining (score 0), 23 (28.0%) had weakly positive staining 
(score 1), 15 (18.3%) had moderate staining (score 2), and 15 
tumors (18.3%) had strong cytoplasmic staining (score 3). We 
defined scores of 0 and 1 as being indicative of “negative or low 
expression” and scores of 2 and 3 as being indicative of “posi-
tive or high expression.” As a result, 52 tumors (63.4%) had 
low expression, and 30 tumors (36.6%) had high expression.
Correlation between αB-crystallin expression and 
clinicopathological features (Table 1)
αB-crystallin was not correlated with tumor size (p=0.602), 
lymph node status (p=0.403), or distant metastasis (p=0.064). 
However, it was correlated with histological grade (p=0.004) 
and lymphovascular invasion (p=0.022). No statistical corre-
lation was found between αB-crystallin score and lymph node 
metastasis (Figure 2). Six of nine cases who developed distant 
metastasis positively expressed αB-crystallin. Although the 
patient population was small and the p value was >0.05, αB-
crystallin expression tended to have a marginal association 
with distant metastasis. Furthermore, when lymph node sta-
tus was classified into pN stages by the number of metastatic 
lymph nodes, αB-crystallin was expressed more strongly in 
pN2 than in pN0 or pN1 (p=0.020) (Figure 3). 
Correlation between αB-crystallin expression and breast 
tumor markers 
αB-crystallin expression was associated with PR (p=0.030) 
Table 1. Correlation between αB-crystallin expression and patient’s 
clinicopathological features
Clinicopathologic feature 
(n=82)
αB-crystallin expression
p-value*
Negative Positive
Tumor size (cm) 0.602
   ≤2 24 20
   >2, ≤5 24   8
   ≥5   4   2
Lymph node metastasis 0.403
   Negative 24 11
   Positive 28 19
pN 0.020
   pN0 (LN=0) 24 11
   pN1 (LN=1-3) 15   3
   pN2 (LN ≥4)  13 16
Histologic grades 0.004
   1 15   1
   2 27 15
   3 10 14
Lymphovascular invasion 0.022
   Negative 31 10
   Positive 21 20
Distant metastasis (n=74) 0.064
   Negative 43 22
   Positive   3   6
LN=number of lymph node metastases.
*Statistical analysis was performed with the chi-square test. p<0.05 was con-
sidered significant.
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Figure 2. αB-crystallin score distributions among patients with lymph 
node negative and lymph node positive breast cancer. No statistical 
correlation was found between αB-crystallin score and each group.αB-Crystallin in Breast 17
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and triple negative breast cancer (TNBC) (p=0.004). A total 
of 60% of the TNBCs were αB-crystallin positive, whereas 
26.8% of non-TNBCs were αB-crystallin positive. Other fac-
tors such as ER, HER2, cytokeratin 5/6 (CK 5/6), and epider-
mal growth factor receptor (EGFR) had no association with 
αB-crystallin expression (Table 2).
Time to distant metastasis according to αB-crystallin 
expression 
The difference in the time to distant metastasis between pa-
tients who were αB-crystallin negative and positive was as-
sessed by the Kaplan-Meier method using the log-lank test. 
αB-crystallin expression significantly decreased time to dis-
tant metastasis. A statistical significance was found between 
any type of distant metastasis and αB-crystallin expression 
(p=0.039) (Figure 4). 
DISCUSSION
Clinical indices such as tumor size, grade and axillary lymph 
node metastasis are useful prognostic factors in breast cancer. 
Among these factors, axillary lymph node metastasis is the 
most important prognostic factor for patients with breast can-
cer [9]. Many other studies have been conducted to identify pre-
dictors related to axillary lymph node status. However, no fac-
tor accurately predicts axillary lymph node metastasis. 
Recently, Chelouche-Lev et al. [5] found significantly more 
αB-crystallin-positive tumors among patients with lymph node-
positive disease than patients with lymph node-negative dis-
ease (p<0.001). They reported that constitutive αB-crystallin 
expression in human breast cancer cells in vitro was associated 
with the ability to metastasize in nude mice, and that the high-
est expression levels were observed in cell lines established from 
metastatic cells. Similarly, αB-crystallin staining was signifi-
cantly associated with lymph node metastasis in our study. 
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Figure 3. αB-crystallin expression according to the number of metasta- 
tic lymph nodes (pN stage). αB-crystallin expression in breast cancers 
was expressed more strongly in pN2 than in pN0 and pN1 (p=0.006).
Figure 4. Time to distant metastasis based on αB-crystallin expression. 
αB-crystallin expression significantly decreased time to distant metasta-
sis. Statistical significance was found between any type of distant me-
tastasis and αB-crystallin expression (p=0.039).
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Table 2. Correlation between αB-crystallin expression and tumor markers
Tumor marker
αB-crystallin expression
p-value*
Negative Positive
ER (n=81)
   Negative 23 19 0.113
   Positive 28 11
PR (n=81)
   Negative 23 21 0.030
   Positive 28 9
HER2 (n=81)
   Negative 37 25 0.269
   Positive 14 5
CK5/6 (n=9)
   Negative 4 2 0.167
   Positive 0 3
EGFR (n=9)
   Negative 2 4 0.167
   Positive 3 0
p53 (n=80)
   Negative 35 18 0.360
   Positive 15 12
Ki-67 (n=57)
   Negative 16 14 0.911
   Positive 14 13
c-kit (n=67)
   Negative 18 9 0.580
   Positive 24 16
TNBC (n=81)
   Negative 41 15 0.004
   Positive 10 15
ER=estrogen receptor; PR=progesterone receptor; CK5/6=cytokeratin5/6; 
EGFR=epidermal growth factor receptor; TNBC=triple negative breast can  cer.
*Statistical analysis was performed with the chi-square test. p<0.05 was con-
sidered significant. 18   Hae Sung Kim, et al.
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However, in this study, αB-crystallin was expressed significant-
ly more in the pN2 breast cancer group than in pN0 or pN1 
groups, which was different from Chelouche-Lev’s study. We 
thought that the differences in the patient cohorts made it dif-
ficult to compare the results of Chelouche-Lev et al. with ours. 
Although αB-crystallin seemed to be associated with lymph 
node metastasis, we do not think αB-crystallin is an accurate 
enough factor to eliminate axillary lymph node dissection. We 
thought that other factors co-expressed with αB-crystallin such 
as stromal cell-derived factor-1 and its receptor, CXC chemo-
kine receptor 4 [10] need to be studied to accurately predict 
prognosis and survival. 
Additionally, 60% of TNBCs were αB-crystallin positive, 
whereas 26.8% of non-TNBCs were αB-crystallin positive. αB-
crystallin may be associated with TNBC. Patients with a TNBC 
had significantly shorter survival following the first metastatic 
event than those with a non-TNBC [11,12]. As most BLBCs 
are ER-negative and HER2-negative, the term TNBC has pre-
viously been substituted for BLBCs [13]. Although there is over-
lap between TNBC and BLBC, 76% of BLBCs expressed either 
EGFR or CK5/6, and these markers define BLBCs [14]. Both 
gene expression data and a recent immunohistochemistry anal-
ysis of breast cancer tissue have suggested an association be-
tween αB-crystallin and BLBCs [15]. The gene expression data 
revealed that αB-crystallin is included in the basal-like gene 
cluster [5,16,17]. αB-crystallin is commonly expressed in BLBCs 
and is thought to be a sensitive (81%) and specific (100%) mark-
er for BLBCs [18]. These studies provide additional indepen-
dent validation linking αB-crystallin to BLBCs [18]. We did not 
find a relationship between BLBC and αB-crystallin because 
of insufficient immunohistochemistry staining for CK5/6 and 
EGFR. 
It seems that αB-crystallin is resistant to neoadjuvant chemo-
therapy. Ivanov et al. [19] reported that αB-crystallin-positive 
tumors had poorer overall response rates than αB-crystallin-
negative tumors (clinical overall response rate, 21% vs. 59%, 
respectively, p=0.005; overall pathological response rate, 16% 
vs. 70%, respectively, p<0.001). 
Despite the pathogenic significance of αB-crystallin, the reg-
ulatory mechanism of its expression related to aggressiveness is 
poorly understood. Heat-shock proteins such as αB-crystallin 
play a major role in the ability of in vitro tumor cells to over-
come stress caused by external stimuli, and enhance resistance 
to apoptosis [20,21]. Such resistance may result from the par-
tial binding of αB-crystallin to caspase-3 and the resulting in-
hibition of the autoproteolytic maturation of caspase-3, a key 
effector molecule in the apoptotic cascades [22]. These findings 
suggest that the anti-apoptotic effect of αB-crystallin may be 
related to the aggressiveness of breast cancer. Furthermore, 
recent research shows that Ets1, an oncogenic transcription 
factor, binds to the αB-crystallin promoter and regulates its 
expression through an ETS-binding site dependent mechanism. 
Ets1 overexpression in breast cancer cells increases αB-crystallin 
protein level, whereas silencing Ets1 reduces αB-crystallin lev-
els. Moreover, Ets1 is expressed in BLBC and is associated with 
poor survival [8]. The rapid time to distant metastasis in our 
study may be linked to these in vitro findings. 
Consistent with earlier studies, we demonstrated that αB-
crystallin expression was associated with poor prognosis such 
as axillary lymph node metastasis in pN2, TNBC, and rapid 
time to recurrence. We think that αB-crystallin could be used 
as an oncoprotein to predict poor clinical outcomes. However, 
further studies are needed to prospectively elucidate the role of 
this novel tumor marker as a clinical prognostic factor in breast 
cancer.
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